BridgeBio Pharma, Inc.
BBIO
$45.95
$1.142.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.20% | 1,882.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.20% | 1,882.88% | |||
| Cost of Revenue | 38.42% | 26.63% | |||
| Gross Profit | -6.21% | 2,901.42% | |||
| SG&A Expenses | 21.43% | 12.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.71% | -2.98% | |||
| Operating Income | -28.58% | 53.10% | |||
| Income Before Tax | -7.10% | 36.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.34% | 36.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -15.14% | -6.54% | |||
| Net Income | -8.65% | 36.83% | |||
| EBIT | -28.58% | 53.10% | |||
| EBITDA | -28.91% | 53.39% | |||
| EPS Basic | -8.44% | 37.07% | |||
| Normalized Basic EPS | -22.97% | 44.20% | |||
| EPS Diluted | -8.44% | 37.07% | |||
| Normalized Diluted EPS | -22.97% | 44.20% | |||
| Average Basic Shares Outstanding | 0.20% | 0.37% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||